Loading data for ENGNW — first visit, this takes a few seconds.
enGene Therapeutics Inc. (ENGNW) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 0
- Market Cap
- n/a
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -127M
- -0.27
- n/a
- n/a
- n/a
- P/B (ttm)
- 0.07
- P/S (ttm)
- n/a
- Earnings Date
- n/a
- Ask
- 0
- Volume
- 1,814
- Avg. Volume (20D)
- n/a
- Open
- 2.10
- Previous Close
- 0.23
- Day's Range
- 0.23 - 0.23
- 52-Week Range
- 0.23 - 0.23
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About enGene Therapeutics Inc.
View profile →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
IPO Date Jul 17, 2026
Employees 81
Stock Exchange NasdaqCM
Ticker Symbol ENGNW
Website https://www.engene.com